Generalized hyperpigmentation with daunorubicin chemotherapy

Journal of the American Academy of Dermatology

Volumn 46, Issue 2, 2002, Pages S1-S3

  Kroumpouzos, George ^a   Travers, Robin ^a   Allan, Anne ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pathology Services Inc Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; MELANIN; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AFRICAN AMERICAN; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL EXAMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; LABORATORY TEST; MALE; MELANOGENESIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN EXAMINATION; SUN EXPOSURE; XEROSIS; ACUTE GRANULOCYTIC LEUKEMIA; CHEMICALLY INDUCED DISORDER; NEGRO; PATHOLOGY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; HUMANS; HYPERPIGMENTATION; LEUKEMIA, MYELOCYTIC, ACUTE; MALE;

EID: 17344383166     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.104509     Document Type: Article

References (17)

1. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999;40:367-98.
2. Priestman TJ, James KW. Adriamycin and longitudinal pigmented banding of fingernails. Lancet 1975;1:1337-8.
3. Daniel CR, Osmel LS. Nail pigmentation abnormalities. Cutis 1982;30:348-60.
4. Law IP. Doxorubicin and unusual skin manifestations. Arch Dermatol 1977;133:379-80.
5. Morris D, Aisner J, Wiernik PH. Horizontal pigmented banding of the nails in association with Adriamycin chemotherapy. Cancer Treat Rep 1977;61:499-501.
6. Kew MC, Mzmane D, Smith AG, Shuster S. Melanocyte-stimulating hormone levels in doxorubicin-induced hyperpigmentation. Lancet 1977;1:811.
7. Demarinis M, Hendricus A, Stoltzner G. Nail pigmentation with daunorubicin therapy. Ann Intern Med 1978;89:516-7.
8. Anderson LL, Thomas DE, Berger TG, Vukelja SJ. Cutaneous pigmentation after daunorubicin chemotherapy. J Am Acad Dermatol 1992;26:255-6.
9. Kelly TM, Fishman LM, Lessner HE. Hyperpigmentation with daunorubicin therapy. Arch Dermatol 1984;120:262-3.
10. Stefanato CM, Bhawan J. Diffuse hyperpigmentation of the skin: a clinicopathologic approach to diagnosis. Sem Cutaneous Med Surg 1997;16:61-71.
11. Varga J, Asato N, Lande S, Lerner AB. Melanotropin-daunorubicin conjugate shows receptor-mediated cytotoxicity in cultures of murine melanoma cells. Nature 1977;267:56-8.
12. Odel DW. Melanocyte-stimulating hormones, lipotropins, the endorphins, and enkephalins. In: DeGroot LJ, Cahill GF, Odel WD, Martini L, Potts JT, Nelson DH, et al, editors. Endocrinology. New York: Grune and Stratton Inc; 1979. p. 169-73.
13. Pilgram WJ, Fuller W, Hamilton LD. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature 1972;235:17-9.
14. Jimbow K, Quevedo WC Jr, Fitzpatrick TB, Szabo G. Age changes and the melanocyte system. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general medicine.4th ed. New York, NY:McGraw-Hill; 1993.p.265-8.
15. Eller MS, Yaar M, Gilchrest BA.DNA damage and melanogenesis. Nature 1994;372:413-4.
16. Calsou P, Sage E, Moustachi E, Salles B. Preferential repair incision of cross-links versus monoadducts in psoralen-damaged plasmid DNA by human cell-free extracts. Biochemistry 1996;35:14963-9.
17. Vasil'eva SV, Makhova EV, Efremenkova OV, Bartoshevich IuE. Genotoxic and mutagenic activity of antineoplastic anthracyclines and their aglycones: study in two test-systems. Genetika 1996;32:233-9.